Rocket


Overview
Financials
News + Filings
Key Docs
Ownership





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Ascendis Pharma A/S (ASND)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-16Dec-31-15Dec-31-14Dec-31-13Dec-31-12
   20-F20-F20-F20-F20-F
Revenues  0.00.00.00.00.0
            Revenue growth  -43.3%-41.9%-31.5%31.0% 
Cost of goods sold  0.00.00.00.00.0
Gross profit  0.00.00.00.00.0
            Gross margin  100.0%100.0%100.0%100.0%100.0%
Selling, general and administrative   [+]0.00.00.00.00.0
Research and development  0.10.00.00.00.0
EBIT   [+]-0.10.00.00.00.0
            EBIT margin  -1583.2%-515.2%-85.7%25.9%9.7%
Other income (expense), net  0.00.00.00.00.0
Pre-tax income  -0.10.00.00.00.0
Income taxes  0.00.00.00.00.0
            Tax rate  0.3%1.9%6.6%13.3%2.7%
Net income  -0.10.00.00.00.0
            Net margin  -1487.3%-405.5%-69.1%20.0%8.0%
   
Basic EPS   [+]($2.58)($1.39)($0.85)$0.38$0.10
Diluted EPS   [+]($2.58)($1.39)($0.85)$0.32$0.01
   
Shares outstanding (basic)   [+]0.00.00.00.00.0
Shares outstanding (diluted)   [+]0.00.00.00.00.1
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy